Ion Channels as Pharmacological Targets in Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 November 2024 | Viewed by 106
Special Issue Editors
Interests: pharmacology; ion channels; acquired channelopathies (cancer); pancreatic cancer; rare diseases; genetic channelopathies; non-dystrophic myotonias; drug repurposing; precision medicine
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology; ion channels; cancer; multiple myeloma; pancreatic cancer; tumor microenvironment; non-dystrophic myotonias; drug repurposing; precision medicine
Special Issues, Collections and Topics in MDPI journals
Interests: colon cancer; TRP channels; tumor microenvironment; gastrointestinal diseases; inflammation; colitis-associated cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Despite the significant advances in the identification and targeting of new molecular drivers of cancer, some of these targets have eluded drug treatments thus far.
In this scenario, the targeting of ion channels has emerged as a promising novel approach in cancer treatment. Indeed, the altered expression and/or function of these proteins have been associated with tumor aggressiveness and increased proliferation, migration, invasion and metastasis of cancer cells. Furthermore, it has been demonstrated that ion channels are also involved in the control or sensing of the tumor microenvironment, in the development of chemoresistance and in the modulation of intracellular signaling.
This evidence makes ion channels promising targets for fighting cancer through the identification of new pharmacological agents, drug repositioning and feasibly the use of target therapies, including monoclonal antibodies.
The aim of this Special Issue is to publish original papers and reviews dealing with the role of ion channels in cancer progression, therapy and chemoresistance.
Dr. Concetta Altamura
Dr. Ilaria Saltarella
Dr. Ester Pagano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ion channels
- cancer
- cancer pharmacology
- target therapies
- personalized therapy
- chemoresistance
- oncology
- channelopathies
